Odyssey Health, Inc.
For the period ended Apr 30, 2026. Filed Jun 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Apr 30, 2026 · Filed Jun 12, 2026
ODYYStored price and day change unavailable
What changed in Management’s Discussion and Analysis?
Read the current filingPrevious report: 10-Q
Period ended 2026-01-31; filed 2026-03-12.
0001683168-26-001695
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of OperationsCurrent report: 10-Q
Period ended 2026-04-30; filed 2026-06-12.
0001683168-26-004820
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of OperationsThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 47 previous paragraphs and 48 current paragraphs.
39 unchanged; 7 reworded; 2 added; 1 removed; 0 previous and 0 current paragraphs rearranged.
Tables are not compared: 8 previous and 8 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
Added paragraphs (2)
Current report
Gain on Extinguishment of Accounts Payable
Current report
Gain on extinguishment of accounts payable in the Fiscal 2026 periods relates to a total of $85,369 of accounts payable and accrued wages that were forgiven by a total of five vendors.
Removed paragraphs (1)
Previous report
nm: Not meaningful
Reworded paragraphs (7)
Previous wording
Other than as described in Note 1 of Notes to Condensed Consolidated Financial Statements, during the six months ended January 31, 2026, there were no significant changes to our significant accounting policies and estimates as described in Note 2.Summary of Significant Accounting Policies included in Part II, Item 8. of our Annual Report on Form 10-K for the year ended July 31, 2025, which was filed with the SEC on October 29, 2025.
Current wording
Other than as described in Note 1 of Notes to Condensed Consolidated Financial Statements, during the nine months ended April 30, 2026, there were no significant changes to our significant accounting policies and estimates as described in Note 2.Summary of Significant Accounting Policies included in Part II, Item 8. of our Annual Report on Form 10-K for the year ended July 31, 2025, which was filed with the SEC on October 29, 2025.
Previous wording
We provide maintenance and related services for a commercial facility pursuant to our Maintenance Agreement with Mast Hill Fund, L.P. beginning November 13, 2025 and ending on the first business day of February 2034. In exchange, Mast Hill pays us service fees which currently total $245,000 per year. We do not currently sell or market any products. We will commence actively marketing products after the products and drugs in development have been FDA cleared or approved, but there can be no assurance, however, that we will be successful in obtaining FDA clearance or approval for our products.
Current wording
We provide maintenance and related services for a commercial facility pursuant to our Maintenance Agreement with Mast Hill Fund, L.P. beginning November 13, 2025 and ending on the first business day of February 2034. In exchange, Mast Hill pays us service fees which currently total approximately $252,450 per year. We do not currently sell or market any products. The service fees are recorded as an offset to the Maintenance note principal and accrued interest. We will commence actively marketing products after the products and drugs in development have been FDA cleared or approved, but there can be no assurance, however, that we will be successful in obtaining FDA clearance or approval for our products.
Previous wording
The changes in General and administrative expense were due to the following:
Current wording
The net decreases in General and administrative expense were due to the following:
Previous wording
The decrease in public company expense for the six months ended January 31, 2026 was due to lower securities filing activity. The increase in wages for the three months ended January 31, 2026 was due to wages paid to our officers. The decrease in wages for the six months ended January 31, 2026, was due to a voluntary decrease in executive salaries. The decreases in stock-based compensation were due to no stock-based compensation in the three and six months of fiscal 2026 due to no equity awards being granted and no unrecognized stock-based compensation. The decreases were offset by increases in business development and investor relations expense primarily related to our agreement with NeuRX Health, Inc. and associated investor relations outreach. See Note 3 of Notes to Condensed Consolidated Financial Statements.
Current wording
The decrease in public company expense for the nine months ended April 30, 2026 was due to lower securities filing activity. The increase in wages for the three months ended April 30, 2026 was due to full wages being paid to our officers. The increase in wages for the nine months ended April 30, 2026 was offset by a voluntary decrease in executive salaries in the first two quarters of Fiscal 2026. The decreases in stock-based compensation were due to no stock-based compensation in the three and nine months of fiscal 2026 due to no equity awards being granted and no unrecognized stock-based compensation. The increases in business development and investor relations expense primarily related to our agreement with NeuRX Health, Inc. and associated investor relations outreach. See Note 3 of Notes to Condensed Consolidated Financial Statements.
Previous wording
Financing costs in the fiscal 2026 periods included the following:
Current wording
Financing costs in fiscal 2026 included the following:
Previous wording
Change in fair value of derivative liabilities in the fiscal 2026 periods relates to the value of the variable conversion feature embedded in our August 27, 2025 SPA and November 13, 2025 SPA with Mast Hill. See Notes 4 and 5 of Notes to Condensed Consolidated Financial Statements for additional information.****
Current wording
Change in fair value of derivative liabilities in the Fiscal 2026 periods relates to the value of the variable conversion features embedded in our August 27, 2025 SPA and November 13, 2025 SPA with Mast Hill. See Notes 4 and 5 of Notes to Condensed Consolidated Financial Statements for additional information.
Previous wording
To date, we have financed our operations primarily through debt financing and limited sales of our common stock. Our ability to continue to access capital could be affected adversely by various factors, including general market and other economic conditions, interest rates, the perception of our potential future earnings and cash distributions, any unwillingness on the part of lenders to make loans to us, and any deterioration in the financial position of lenders that might make them unable to meet their obligations to us. If these conditions continue and we cannot raise funds through a public or private debt financing, or an equity offering, our ability to grow our business may be negatively affected. In such case, we would suspend research and development activities until market conditions improve.
Current wording
To date, we have financed our operations primarily through debt financing and limited sales of our common stock. Our ability to continue to access capital could be affected adversely by various factors, including general market and other economic conditions, interest rates, the perception of our potential future earnings and cash distributions, any unwillingness on the part of lenders to make loans to us and any deterioration in the financial position of lenders that might make them unable to meet their obligations to us. If these conditions continue and we cannot raise funds through a public or private debt financing, or an equity offering, our ability to grow our business may be negatively affected. In such case, we have suspended research and development activities until market conditions improve.